All variants were in two known glioma regions: 11 variants in PHLDB1 (most significant rs7125115, meta P = 1.73 × 10−13, Mayo GWAS OR = 1.48) and 10 variants in D2HGDH (most significant rs71430382, meta P = 8.86 × 10−10, Mayo GWAS OR = 1.65). This evidence concerns the gene PHLDB1 and central nervous system cancer.